InMed Pharmaceuticals Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric A. Adams Chem.
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 815 West Hastings Street Vancouver BC Canada V6C 1B4
- IPO Date
- May 5, 2014
- CIK
- 0001728328
- Website
- inmedpharma.com
- Similar Companies
- Business
- InMed Pharmaceuticals Inc. InMed Pharmaceuticals Inc. (NASDAQ: INM) is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, Canada, and founded in 2014 that develops a pipeline of proprietary small molecule drug candidates targeting CB1 and CB2 receptors for diseases with high unmet medical needs, including Alzheimer's disease, age-related macular degeneration and epidermolysis bullosa; its lead candidates comprise INM-901, which demonstrates neuroprotective effects, neurite outgrowth promotion, neuroinflammation reduction and favorable behavioral outcomes in preclinical Alzheimer's models, INM-089, which provides neuroprotection to photoreceptors, improves retinal pigment epithelium integrity and reduces extracellular autofluorescent deposits in dry AMD preclinical studies, and INM-755, a completed Phase 2 topical cannabinol cream for epidermolysis bullosa with potential expansion to broader dermatological indications such as chronic severe itching; through its subsidiary BayMedica, the company manufactures and commercializes premium, bioidentical rare cannabinoids including cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV) and cannabicitran (CBTC) as high-purity, THC-free active pharmaceutical ingredients for the health and wellness industry, supported by its IntegraSyn proprietary biosynthesis system for cost-effective production of pharmaceutical-grade cannabinoids. The company operates primarily in North America with a focus on pharmaceutical research, development and manufacturing. In recent developments, InMed strengthened its intellectual property portfolio through the issuance of three new U.S. patents covering INM-755 formulations and uses, biosynthesis manufacturing processes and ocular drug delivery, alongside additional patent filings for INM-901 in neurodegenerative conditions; advanced INM-901 with molecular analysis of long-term preclinical Alzheimer's studies confirming statistically significant neuroinflammation reduction and oral formulation feasibility, alongside plans for chemistry, manufacturing and controls development toward an investigational new drug application; demonstrated INM-089 intravitreal formulation progress for dry AMD; appointed Dr. Barry Greenberg of Johns Hopkins to its scientific advisory board; entered a standby equity purchase agreement; implemented a share consolidation to meet Nasdaq listing requirements following a hearings panel exception; and reported fiscal 2025 quarterly results with BayMedica sales growth while prioritizing pipeline acceleration.
Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT
InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
/C O R R E C T I O N -- InMed Pharmaceuticals/
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
InMed Pharmaceuticals Amends Preferred Investment Options
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
InMed Pharmaceuticals Amends Preferred Investment Options
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript